These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Author: Borchmann P.
    Journal: Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068.
    Abstract:
    The key question in advanced-stage Hodgkin lymphoma for many years now has been, should intensified chemotherapy be applied upfront or be reserved for relapsing patients. The early intensification approach with BEACOPP(escalated) (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) aims at curing patients with first-line chemotherapy definitely. The added toxicity of this approach as compared to less intensive regimens as ABDV (doxorubicin, bleomycin, dacarbazine, vinblastine) is mainly restricted to acute haematotoxicity and gonadal damage. However, regarding efficacy, there is a meaningful survival-benefit over ABVD (10% at 5years) and the intensified first-line treatment strategy is thus rightly regarded as standard of care.
    [Abstract] [Full Text] [Related] [New Search]